FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis

PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease…Original Article